A final rule from the Centers for Medicare & Medicaid Services (CMS) will require the inclusion of wholesale acquisition cost, or list price, in direct-to-consumer (DTC) television advertisements for prescription pharmaceuticals covered by Medicaid or Medicare.
The rule applies to prices equal to or greater than $35 for a month’s supply or the usual course of therapy.1
In announcing the requirement, US Department of Health and Human Services (HHS) Secretary Alex Azar said that people in the United States deserve to know the prices of the drugs they receive.1
“Patients who are struggling with high drug costs are in that position because of the high list prices that drug companies set. Making those prices more transparent is a significant step in [President Donald J. Trump’s] efforts to reform our prescription drug markets and put patients in charge of their own health care,” Azar said in a statement.1
The final rule is an important step for lowering prescription drug prices through transparency, CMS Administrator Seema Verma said.1